[Elsevier] Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial

Biafer Post time 9 hour(s) ago | Show all posts |Read mode
This post will be closed automatically in 2026-11-02 01:11
Reward10points


Reply

Use magic Donate Report

All Reply0 Show all posts

Reply

You have to log in before you can reply Login | Register

Points Rules

Intermediate member
  • post

  • reply

  • points

    380


Return to the list